Stuart L. Goldberg, MD, on Approaching Biomarker Testing with Patients

Article

The expert spoke about the best way for physicians to discuss biomarker testing with their patients to ensure that they have an understanding and can make the right decisions for their treatment.

Stuart L. Goldberg, MD, from Hackensack University Medical Center, discussed how health care providers should approach the topic of biomarker testing with their patients so that they are better informed and can make proper treatment decisions in an interview with CancerNetwork®

Transcription:

Well, talking to our patients about genomics is no different than talking to them about their underlying cancer. We need to spend the time, we need to think about what the patient’s education level is, so that we communicate in a way that they can understand. We don’t want to give them information overload, especially during a critical time when they’re just diagnosed, and they’re scared about it. But at the same time, we can’t hold back information that’s important to making a decision. 

 

I think that if we think about the patient, you know, if it were our loved one, what’s the information that we would want them to have to make the right decisions and to understand what we’re doing. And we don’t have to give it all in the first visit. We can, you know, we’re going to have our long-term relationship with these patients. We want to make sure that we spoon that information out over time as they learn more about their disease. So, communicating genomics is no different than communicating about cancer therapies, which we’ve done for years. It’s just now a new part of what we have to talk about. 

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Related Content